AbbVie Inc (ABBV)vsAbeona Therapeutics Inc (ABEO)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
ABEO
Abeona Therapeutics Inc
$5.34
-0.37%
HEALTHCARE · Cap: $303.75M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1050759% more annual revenue ($61.16B vs $5.82M). ABEO leads profitability with a 1223.0% profit margin vs 6.9%. ABEO trades at a lower P/E of 5.3x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ABEO
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+81.8%
Fair Value
$27.73
Current Price
$5.34
$22.39 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 70 in profit
Keeps 1223 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 100.0%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ABEO
The strongest argument for ABEO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 1223.0% and operating margin at -422.7%.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ABEO
The primary concerns for ABEO are EPS Growth, Market Cap, Revenue Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while ABEO is a declining play — different risk/reward profiles.
ABEO carries more volatility with a beta of 1.21 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 46/100). ABEO offers better value entry with a 81.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Abeona Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for rare, life-threatening genetic diseases. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?